Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The phase 3 SELECT trial highlighted semaglutide 2.4 mgs capability to cut the risk of major adverse cardiovascular events by 20% in individuals with obesity compared to a placebo, leading to an updated label for Wegovy
A clinically positioned GLP-1 metabolic support product provides a credible foundation for building a broader brand ecosystem that may include gut health, muscle preservation, collagen support, energy optimization, and longevity nutrition
A common and dangerous mistake is continuing to draw the same number of units from a new concentration vial
Clinical trial data show that hair loss is a side effect of retatrutide, particularly in individuals with a predisposition to hair loss or existing metabolic disorders
Meanwhile, lawmakers in Louisiana are debating whether to allow Medicaid to cover GLP-1s for obesity treatment if enrollees have another chronic condition, or comorbidity, such as prediabetes, hypertension or cardiovascular disease
US$ 28.13
US$ 29.35
US$ 24.99
US$ 21.71
